| http://dbpedia.org/ontology/abstract
|
Fremanezumab, sold under the brand name Aj … Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults. It is given by injection under the skin. The most common side effect is pain and redness at the site of injection. Other side effects include allergic reactions. It is in the calcitonin gene-related peptide antagonist class of medications. It was approved for medical use in the United States in 2018, the European Union in 2019 and the UK in 2020.European Union in 2019 and the UK in 2020.
, Fremanezumab, venduto con il marchio Ajovy … Fremanezumab, venduto con il marchio Ajovy, è un farmaco usato per prevenire l'emicrania. Viene somministrato per via sottocutanea. L'effetto collaterale più comune è il dolore e il rossore nel sito di iniezione. Altri effetti collaterali includono reazioni allergiche. È nella classe di farmaci antagonisti del peptide correlato al gene della calcitonina. È stato approvato per uso medico negli Stati Uniti d'America nel 2018. Il costo all'ingrosso negli Stati Uniti d'America a partire dal 2019 è di 369,90 USD al mese. partire dal 2019 è di 369,90 USD al mese.
, Le frémanézumab est un anticorps monoclonal dirigé contre le peptide relié au gène de la calcitonine (PRGC) et utilisé dans le traitement des migraines.
, يُباع فريمانيزوماب تحت الاسم التجاري أجوفي … يُباع فريمانيزوماب تحت الاسم التجاري أجوفي، وهو دواء يستخدم لمنع الصداع النصفي عند البالغين. يعطى عن طريق الحقن تحت الجلد. التأثير الجانبي الأكثر شيوعًا هو الألم والاحمرار في موقع الحقن. تشمل الآثار الجانبية الأخرى تفاعلات الحساسية. إنه موجود في فئة الأدوية المضادة للببتيد المرتبط بالجينات من الكالسيتونين. تمت الموافقة عليه للاستخدام الطبي في الولايات المتحدة في عام 2018، الاتحاد الأوروبي في عام 2019 والمملكة المتحدة في عام 2020. في عام 2019 والمملكة المتحدة في عام 2020.
, Fremanezumab (Handelsname: Ajovy) ist ein humanisierter monoklonaler Antikörper zur Vorbeugung von Migräne. Fremanezumab wird einmal monatlich oder alle 3 Monate als subkutane Injektion mit einer Fertigspritze oder einem Fertigpen verabreicht.
, Fremanezumab, prodávaný pod obchodním názv … Fremanezumab, prodávaný pod obchodním názvem Ajovy, je lék používaný k prevenci migrény u dospělých. Fremanezumab je humanizovaná monoklonální protilátka. Patří do skupiny antagonistů peptidů souvisejících s kalcitoninovým genem. Podává se injekčně pod kůži. Nejčastějším nežádoucím účinkem je bolest a zarudnutí v místě vpichu. Mezi další nežádoucí účinky patří alergické reakce. Pro lékařské použití byl schválen ve Spojených státech v roce 2018, v Evropské unii v roce 2019 a ve Velké Británii v roce 2020. Ve Velké Británii byl v roce 2021 schválen pro použití nejen na chronickou, ale i na epizodickou migrénu. chronickou, ale i na epizodickou migrénu.
|
| http://dbpedia.org/ontology/alternativeName
|
Ajovy
|
| http://dbpedia.org/ontology/bioavailability
|
55
|
| http://dbpedia.org/ontology/casNumber
|
1655501-53-3
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Calcitonin_gene-related_peptide_antagonist +
|
| http://dbpedia.org/ontology/drugbank
|
DB14041
|
| http://dbpedia.org/ontology/fdaUniiCode
|
PF8K38CG54
|
| http://dbpedia.org/ontology/kegg
|
D11055
|
| http://dbpedia.org/ontology/medlinePlus
|
a618053
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/AJOVY.jpg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/fremanezumab +
|
| http://dbpedia.org/ontology/wikiPageID
|
54825223
|
| http://dbpedia.org/ontology/wikiPageLength
|
11867
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1101373629
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Injection_under_the_skin +
, http://dbpedia.org/resource/Kidney +
, http://dbpedia.org/resource/Pfizer +
, http://dbpedia.org/resource/Cytochrome_P450 +
, http://dbpedia.org/resource/Bioavailability +
, http://dbpedia.org/resource/US_Food_and_Drug_Administration +
, http://dbpedia.org/resource/Amino_acid +
, http://dbpedia.org/resource/Subcutaneous_injection +
, http://dbpedia.org/resource/Proteolysis +
, http://dbpedia.org/resource/Hypersensitivity +
, http://dbpedia.org/resource/Chinese_hamster_ovary_cell +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Migraine +
, http://dbpedia.org/resource/Recombinant_DNA +
, http://dbpedia.org/resource/Placebo +
, http://dbpedia.org/resource/Peptide +
, http://dbpedia.org/resource/Ergot_alkaloid +
, http://dbpedia.org/resource/Rinat_Neuroscience_Corporation +
, http://dbpedia.org/resource/Calcitonin_gene-related_peptide_antagonist +
, http://dbpedia.org/resource/Cluster_headache +
, http://dbpedia.org/resource/Calcitonin_gene-related_peptide +
, http://dbpedia.org/resource/Elimination_half-life +
, http://dbpedia.org/resource/Triptan +
, http://dbpedia.org/resource/Monoclonal_antibody +
, http://dbpedia.org/resource/Teva_Pharmaceutical_Industries +
, http://dbpedia.org/resource/Category:Antimigraine_drugs +
|
| http://dbpedia.org/property/atcPrefix
|
N02
|
| http://dbpedia.org/property/atcSuffix
|
CD03
|
| http://dbpedia.org/property/bioavailability
|
55
|
| http://dbpedia.org/property/c
|
6470
|
| http://dbpedia.org/property/caption
|
A Norwegian syringe of fremanezumab
|
| http://dbpedia.org/property/casNumber
|
1655501
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Calcitonin_gene-related_peptide_antagonist +
|
| http://dbpedia.org/property/dailymedid
|
Fremanezumab
|
| http://dbpedia.org/property/drugbank
|
DB14041
|
| http://dbpedia.org/property/eliminationHalfLife
|
-2678400.0
|
| http://dbpedia.org/property/excretion
|
http://dbpedia.org/resource/Kidney +
|
| http://dbpedia.org/property/h
|
9952
|
| http://dbpedia.org/property/kegg
|
D11055
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalCa
|
Rx-only / Schedule D
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalStatus
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/licenceEu
|
yes
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/medlineplus
|
a618053
|
| http://dbpedia.org/property/metabolism
|
http://dbpedia.org/resource/Proteolysis +
|
| http://dbpedia.org/property/n
|
1716
|
| http://dbpedia.org/property/o
|
2016
|
| http://dbpedia.org/property/pregnancyAu
|
B1
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Subcutaneous_injection +
|
| http://dbpedia.org/property/s
|
46
|
| http://dbpedia.org/property/source
|
zu
|
| http://dbpedia.org/property/synonyms
|
TEV-48125, fremanezumab-vfrm
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/Calcitonin_gene-related_peptide +
|
| http://dbpedia.org/property/tradename
|
Ajovy
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
PF8K38CG54
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:When +
, http://dbpedia.org/resource/Template:Triptans +
, http://dbpedia.org/resource/Template:Monoclonals_for_bone%2C_musculoskeletal%2C_circulatory%2C_and_neurologic_systems +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Citation_needed +
, http://dbpedia.org/resource/Template:Update_inline +
, http://dbpedia.org/resource/Template:Short_description +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Antimigraine_drugs +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Fremanezumab?oldid=1101373629&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/AJOVY.jpg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Fremanezumab +
|
| owl:sameAs |
http://vi.dbpedia.org/resource/Fremanezumab +
, http://no.dbpedia.org/resource/Fremanezumab +
, http://dbpedia.org/resource/Fremanezumab +
, http://www.wikidata.org/entity/Q39048381 +
, http://cs.dbpedia.org/resource/Fremanezumab +
, http://it.dbpedia.org/resource/Fremanezumab +
, http://ar.dbpedia.org/resource/%D9%81%D8%B1%D9%8A%D9%85%D8%A7%D9%86%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8 +
, http://fr.dbpedia.org/resource/Fr%C3%A9man%C3%A9zumab +
, https://global.dbpedia.org/id/3bua2 +
, http://de.dbpedia.org/resource/Fremanezumab +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
|
| rdfs:comment |
Fremanezumab, prodávaný pod obchodním názv … Fremanezumab, prodávaný pod obchodním názvem Ajovy, je lék používaný k prevenci migrény u dospělých. Fremanezumab je humanizovaná monoklonální protilátka. Patří do skupiny antagonistů peptidů souvisejících s kalcitoninovým genem. Podává se injekčně pod kůži. Nejčastějším nežádoucím účinkem je bolest a zarudnutí v místě vpichu. Mezi další nežádoucí účinky patří alergické reakce.í nežádoucí účinky patří alergické reakce.
, Fremanezumab (Handelsname: Ajovy) ist ein humanisierter monoklonaler Antikörper zur Vorbeugung von Migräne. Fremanezumab wird einmal monatlich oder alle 3 Monate als subkutane Injektion mit einer Fertigspritze oder einem Fertigpen verabreicht.
, Le frémanézumab est un anticorps monoclonal dirigé contre le peptide relié au gène de la calcitonine (PRGC) et utilisé dans le traitement des migraines.
, يُباع فريمانيزوماب تحت الاسم التجاري أجوفي … يُباع فريمانيزوماب تحت الاسم التجاري أجوفي، وهو دواء يستخدم لمنع الصداع النصفي عند البالغين. يعطى عن طريق الحقن تحت الجلد. التأثير الجانبي الأكثر شيوعًا هو الألم والاحمرار في موقع الحقن. تشمل الآثار الجانبية الأخرى تفاعلات الحساسية. إنه موجود في فئة الأدوية المضادة للببتيد المرتبط بالجينات من الكالسيتونين. تمت الموافقة عليه للاستخدام الطبي في الولايات المتحدة في عام 2018، الاتحاد الأوروبي في عام 2019 والمملكة المتحدة في عام 2020. في عام 2019 والمملكة المتحدة في عام 2020.
, Fremanezumab, venduto con il marchio Ajovy … Fremanezumab, venduto con il marchio Ajovy, è un farmaco usato per prevenire l'emicrania. Viene somministrato per via sottocutanea. L'effetto collaterale più comune è il dolore e il rossore nel sito di iniezione. Altri effetti collaterali includono reazioni allergiche. È nella classe di farmaci antagonisti del peptide correlato al gene della calcitonina. È stato approvato per uso medico negli Stati Uniti d'America nel 2018. Il costo all'ingrosso negli Stati Uniti d'America a partire dal 2019 è di 369,90 USD al mese. partire dal 2019 è di 369,90 USD al mese.
, Fremanezumab, sold under the brand name Aj … Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults. It is given by injection under the skin. The most common side effect is pain and redness at the site of injection. Other side effects include allergic reactions. It is in the calcitonin gene-related peptide antagonist class of medications. It was approved for medical use in the United States in 2018, the European Union in 2019 and the UK in 2020.European Union in 2019 and the UK in 2020.
|
| rdfs:label |
فريمانيزوماب
, Fremanezumab
, Frémanézumab
|
